Literature DB >> 21499545

Efficient Intracellular Delivery of a Pro-Apoptotic Peptide With A pH-Responsive Carrier.

Brian Albarran1, Allan S Hoffman, Patrick S Stayton.   

Abstract

A key challenge in developing protein therapeutics or imaging agents that work against cytosolic targets is the intracellular delivery barrier. Here, we show that the pH-responsive, membrane-destabilizing polymer, poly (propylacrylic acid) (PPAA), can strongly enhance target cell killing through the intracellular delivery of a functional proapoptotic peptide. The Bak BH3 peptide induces apoptosis via antagonization of suppressor targets such as Bcl-2 and Bcl-x(L). A genetically-engineered streptavidin that contains an N-terminal TAT peptide sequence was used to optimize the pinocytotic cell uptake of biotinylated BH3 peptide and end-biotinylated PPAA. Fluorescence microscopic analysis of DAPI-stained HELA cells was used to quantitate apoptosis. Approximately 30% of cells treated with TAT-SA:BH3 complexes revealed morphologically distinct nuclear condensation, a hallmark of apoptosis. The incorporation of biotinylated PPAA had the effect of markedly enhancing the killing effect of BH3 peptides by an additional 55% (p<0.001) to a total cell killing efficiency of 85%. Caspase-3 activity was up-regulated in a TAT-SA:BH3:PPAA dose-dependent manner. The induction of apoptosis with the TAT-SA:BH3:PPAA complex was abrogated with the L78A BH3 peptide, that had been previously shown to knock-out antagonization activity. The caspase and L78A peptide results demonstrate that the delivered BH3 is indeed working through the biologically relevant apoptosis signaling pathway. These studies establish the ability of PPAA to strongly enhance the intracellular delivery of a functional pro-apoptotic peptide. Together with the PPAA, the TAT-SA adaptor complex could prove useful as a carrier of peptide/protein cargo to cultured cells.

Entities:  

Year:  2011        PMID: 21499545      PMCID: PMC3076797          DOI: 10.1016/j.reactfunctpolym.2010.09.008

Source DB:  PubMed          Journal:  React Funct Polym        ISSN: 1381-5148            Impact factor:   3.975


  22 in total

1.  In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA.

Authors:  S R Schwarze; S F Dowdy
Journal:  Trends Pharmacol Sci       Date:  2000-02       Impact factor: 14.819

2.  Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases.

Authors:  E P Holinger; T Chittenden; R J Lutz
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

3.  Cytoplasmic and nuclear delivery of a TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells.

Authors:  Terra B Potocky; Anant K Menon; Samuel H Gellman
Journal:  J Biol Chem       Date:  2003-09-29       Impact factor: 5.157

4.  Characterisation of cell-penetrating peptide-mediated peptide delivery.

Authors:  Simon W Jones; Richard Christison; Ken Bundell; Catherine J Voyce; Sarah M V Brockbank; Peter Newham; Mark A Lindsay
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

5.  Intracellular traffic and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors.

Authors:  Saly Al-Taei; Neal A Penning; Jeremy C Simpson; Shiroh Futaki; Toshihide Takeuchi; Ikuhiko Nakase; Arwyn T Jones
Journal:  Bioconjug Chem       Date:  2006 Jan-Feb       Impact factor: 4.774

6.  The third helix of the Antennapedia homeodomain translocates through biological membranes.

Authors:  D Derossi; A H Joliot; G Chassaing; A Prochiantz
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

Review 7.  Protein/peptide transduction domains: potential to deliver large DNA molecules into cells.

Authors:  E L Snyder; S F Dowdy
Journal:  Curr Opin Mol Ther       Date:  2001-04

8.  Erythrocyte survival is promoted by plasma and suppressed by a Bak-derived BH3 peptide that interacts with membrane-associated Bcl-X(L).

Authors:  Melanie Walsh; Robert J Lutz; Thomas G Cotter; Rosemary O'Connor
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

9.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis.

Authors:  Jehangir S Wadia; Radu V Stan; Steven F Dowdy
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

10.  Internalization of novel non-viral vector TAT-streptavidin into human cells.

Authors:  Johanna Rinne; Brian Albarran; Juulia Jylhävä; Teemu O Ihalainen; Pasi Kankaanpää; Vesa P Hytönen; Patrick S Stayton; Markku S Kulomaa; Maija Vihinen-Ranta
Journal:  BMC Biotechnol       Date:  2007-01-02       Impact factor: 2.563

View more
  5 in total

Review 1.  The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis.

Authors:  Akshay Jain; Kun Cheng
Journal:  J Control Release       Date:  2016-11-16       Impact factor: 9.776

Review 2.  Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.

Authors:  Samir Mitragotri; Paul A Burke; Robert Langer
Journal:  Nat Rev Drug Discov       Date:  2014-08-08       Impact factor: 84.694

3.  Endosomolytic Nano-Polyplex Platform Technology for Cytosolic Peptide Delivery To Inhibit Pathological Vasoconstriction.

Authors:  Brian C Evans; Kyle M Hocking; Kameron V Kilchrist; Eric S Wise; Colleen M Brophy; Craig L Duvall
Journal:  ACS Nano       Date:  2015-06-02       Impact factor: 15.881

4.  Controlled apoptosis by a thermally toggled nanoscale amplifier of cellular uptake.

Authors:  Sarah R MacEwan; Ashutosh Chilkoti
Journal:  Nano Lett       Date:  2014-03-19       Impact factor: 11.189

5.  Biodegradable In Situ Gel-Forming Controlled Drug Delivery System Based on Thermosensitive Poly(ε-caprolactone)-Poly(ethylene glycol)-Poly(ε-caprolactone) Hydrogel.

Authors:  Elham Khodaverdi; Ali Golmohammadian; Seyed Ahmad Mohajeri; Gholamhossein Zohuri; Farnaz Sadat Mirzazadeh Tekie; Farzin Hadizadeh
Journal:  ISRN Pharm       Date:  2012-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.